瑞舒伐他汀对急性心肌梗死患者MMPs及炎症因子的影响  

Effect of rosuvastatin on MMPs and inflammatory factors of elderly patients with acute myocardial infarction

作　　者：左宝功 宋春丽 党岩兵 闫业军[2] 

机构地区：[1]宝鸡市千阳县人民医院,陕西宝鸡721100 [2]宝鸡市中心医院,陕西宝鸡721000

出　　处：《中国热带医学》2016年第10期1032-1035,共4页China Tropical Medicine

摘　　要：目的探讨瑞舒伐他汀对急性心肌梗死患者血清基质金属蛋白酶(matrix metalloproteinases,MMPs)及炎症因子水平的影响。方法选取宝鸡市千阳县人民医院和宝鸡市中心医院急性心肌梗死的老年患者76例,根据随机数字表法分为两组:对照组38例,予阿司匹林、阿托伐他汀等临床常规治疗;试验组38例,在常规治疗基础上加用瑞舒伐他汀,共治疗2周。观察两组患者治疗前后血清MMPs及炎症因子超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、肿瘤坏死因子(tumor necrosis factor-α,TNF-α)及白细胞介素-8(interleukin-8,IL-8)水平的变化,及治疗的临床效果。结果经2周治疗后,试验组患者临床疗效优于对照组,血清MMP-9、MMP-2水平低于对照组(P<0.05);血清hs-CRP、TNF-α及IL-8水平低于对照组(P<0.05);试验组治疗总有效率高于对照组,无效率低于对照组(P<0.05);试验组血管再通率高于对照组,血管闭塞率低于对照组(P<0.05)。结论瑞舒伐他汀能够降低急性心肌梗死患者血清MMPs水平,降低血清hs-CRP、TNF-α及IL-8等炎症因子水平,提高血管再通率,降低血管闭塞率,具有较好的临床疗效。Objective To explore the effect of rosuvastatin on serum levels of matrix metalloproteinases（MMP） andinflammatory factors of elderly patients with acute myocardial infarction. Methods A total of 78 elderly patients with acutemyocardial infarction from our hospital were selected and randomly divided into a control group and an experiment group byrandom number table method, and 38 cases in the control group were treated by aspirin, atorvastatin and other clinical routinetreatment, and 38 cases in the experiment group were treated with rosuvastatin in the bases of the clinical routine treatment.The serum levels of MMPs and inflammatory factors were detected and compared between the two groups, and the efficacy andsafety of atorvastatin in the treatment of elderly patients with acute myocardial infarction were explored. Results After 2 weeksof treatment, the clinical efficacy of the experiment group was significantly better than that of the control group, and theperformance was as following： the serum MMP-9 and MMP-2 levels in the experimental group were lower than those in thecontrol group（P〈0.05）, the hs-CRP, TNF-α and IL-8 levels in the experimental group were lower than those in the controlgroup（P〈0.05）. The total effective rate was higher and the inefficiency was lower in the experimental group compared withthose in the control group（P〈0.05）.The vascular patency rate was higher and the vascular occlusion rate was lower in theexperimental group compared with those in the control group（P〈0.05）. Conclusion Rosuvastatin can reduce the serumlevels of MMPs and inflammatory factors（hs-CRP, TNF- α and IL-8） in the patients with acute myocardial infarction, andimprove the recanalization rate and reduce the vascular occlusion rate, and it has better clinical efficacy.

关 键 词：老年急性心肌梗死 瑞舒伐他汀 血管再通率 炎症因子 基质金属蛋白酶 

分 类 号：R541.4[医药卫生—心血管疾病]